BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, Melero I, Berraondo P. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol 2017;95:347-55. [PMID: 28138156 DOI: 10.1038/icb.2017.6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 17.4] [Reference Citation Analysis]
Number Citing Articles
1 Russick J, Torset C, Hemery E, Cremer I. NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Semin Immunol 2020;48:101407. [PMID: 32900565 DOI: 10.1016/j.smim.2020.101407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
3 Tarazona R, Lopez-Sejas N, Guerrero B, Hassouneh F, Valhondo I, Pera A, Sanchez-Correa B, Pastor N, Duran E, Alonso C, Solana R. Current progress in NK cell biology and NK cell-based cancer immunotherapy. Cancer Immunol Immunother 2020;69:879-99. [PMID: 32130453 DOI: 10.1007/s00262-020-02532-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
4 Cox A, Cevik H, Feldman HA, Canaday LM, Lakes N, Waggoner SN. Targeting natural killer cells to enhance vaccine responses. Trends Pharmacol Sci 2021;42:789-801. [PMID: 34311992 DOI: 10.1016/j.tips.2021.06.004] [Reference Citation Analysis]
5 Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807-21. [PMID: 32612154 DOI: 10.1038/s41423-020-0488-6] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 33.0] [Reference Citation Analysis]
6 Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev 2018;66:104-13. [PMID: 29730461 DOI: 10.1016/j.ctrv.2018.04.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
7 Bhatti MM, Cai AG, Theunissen JW. Binding affinities of human IgG1 and chimerized pig and rabbit derivatives to human, pig and rabbit Fc gamma receptor IIIA. PLoS One 2019;14:e0219999. [PMID: 31323052 DOI: 10.1371/journal.pone.0219999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Shapovalova M, Pyper SR, Moriarity BS, LeBeau AM. The Molecular Imaging of Natural Killer Cells. Mol Imaging 2018;17:1536012118794816. [PMID: 30203710 DOI: 10.1177/1536012118794816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
9 Liu X, Liu C, Zheng Z, Chen S, Pang X, Xiang X, Tang J, Ren E, Chen Y, You M, Wang X, Chen X, Luo W, Liu G, Xia N. Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Adv Mater 2019;31:e1808294. [PMID: 30848011 DOI: 10.1002/adma.201808294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
10 Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 2018;419:210-21. [PMID: 29414305 DOI: 10.1016/j.canlet.2018.01.050] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 32.7] [Reference Citation Analysis]
11 Mandó P, Rizzo M, Roberti MP, Juliá EP, Pampena MB, Pérez de la Puente C, Loza CM, Ponce C, Nadal J, Coló FA, Mordoh J, Levy EM. High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients. Onco Targets Ther 2018;11:2901-10. [PMID: 29844687 DOI: 10.2147/OTT.S160911] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Stergiou N, Urschbach M, Gabba A, Schmitt E, Kunz H, Besenius P. The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. Chem Rec 2021;21:3313-31. [PMID: 34812564 DOI: 10.1002/tcr.202100182] [Reference Citation Analysis]
13 Hanamatsu Y, Saigo C, Kito Y, Takeuchi T. An obstructive role of NK cells on metastatic growth of clear-cell sarcoma cells in a xenoplant murine model. Mol Clin Oncol 2021;14:9. [PMID: 33262889 DOI: 10.3892/mco.2020.2171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. Trends Immunol 2019;40:142-58. [PMID: 30639050 DOI: 10.1016/j.it.2018.12.003] [Cited by in Crossref: 119] [Cited by in F6Publishing: 112] [Article Influence: 39.7] [Reference Citation Analysis]
15 Medina-Echeverz J, Hinterberger M, Testori M, Geiger M, Giessel R, Bathke B, Kassub R, Gräbnitz F, Fiore G, Wennier ST, Chaplin P, Suter M, Hochrein H, Lauterbach H. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Nat Commun 2019;10:5041. [PMID: 31695037 DOI: 10.1038/s41467-019-12998-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Dianat-Moghadam H, Rokni M, Marofi F, Panahi Y, Yousefi M. Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells. J Cell Physiol 2018;234:259-73. [PMID: 30144312 DOI: 10.1002/jcp.26878] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
17 Shen J, Xiang S, Peng M, Zhou Z, Wu Z. Mechanisms of Resistance to Schistosoma japonicum Infection in Microtus fortis, the Natural Non-permissive Host. Front Microbiol 2020;11:2092. [PMID: 33013763 DOI: 10.3389/fmicb.2020.02092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, Dorillo E, Rompietti C, Adamo FM, Ruggeri L, Di Ianni M, Rosati E. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Int J Mol Sci 2021;22:6665. [PMID: 34206399 DOI: 10.3390/ijms22136665] [Reference Citation Analysis]
19 Smyth MJ. Multiple approaches to immunotherapy - the new pillar of cancer treatment. Immunol Cell Biol 2017;95:323-4. [PMID: 28174425 DOI: 10.1038/icb.2017.9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
20 Han X, Vesely MD. Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. Int Rev Cell Mol Biol 2019;342:1-25. [PMID: 30635089 DOI: 10.1016/bs.ircmb.2018.07.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
21 Lenferink AEG, McDonald PC, Cantin C, Grothé S, Gosselin M, Baardsnes J, Banville M, Lachance P, Robert A, Cepero-Donates Y, Radinovic S, Salois P, Parat M, Oamari H, Dulude A, Patel M, Lafrance M, Acel A, Bousquet-Gagnon N, L'Abbé D, Pelletier A, Malenfant F, Jaramillo M, O'Connor-Mccourt M, Wu C, Durocher Y, Duchesne M, Gadoury C, Marcil A, Fortin Y, Paul-Roc B, Acchione M, Chafe SC, Nemirovsky O, Lau J, Bénard F, Dedhar S. Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX. MAbs 2021;13:1999194. [PMID: 34806527 DOI: 10.1080/19420862.2021.1999194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Sivori S, Pende D, Quatrini L, Pietra G, Della Chiesa M, Vacca P, Tumino N, Moretta F, Mingari MC, Locatelli F, Moretta L. NK cells and ILCs in tumor immunotherapy. Mol Aspects Med 2021;80:100870. [PMID: 32800530 DOI: 10.1016/j.mam.2020.100870] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
23 Kim H, Khanna V, Kucaba TA, Zhang W, Sehgal D, Ferguson DM, Griffith TS, Panyam J. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Mol Pharm 2020;17:2109-24. [PMID: 32383885 DOI: 10.1021/acs.molpharmaceut.0c00271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
24 Lin W, Chen M, Hong L, Zhao H, Chen Q. Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Front Oncol 2018;8:532. [PMID: 30519541 DOI: 10.3389/fonc.2018.00532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Yang S, Cao B, Zhou G, Zhu L, Wang L, Zhang L, Kwok HF, Zhang Z, Zhao Q. Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer. Front Pharmacol 2020;11:1089. [PMID: 32848731 DOI: 10.3389/fphar.2020.01089] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
26 Hwang SD, Lee JH, Kim K, Lee SW, Song JH. Effect of Rituximab Used as Induction in Patients with ABO Mismatch Kidney Transplant: A Systematic Review and Meta-analysis. Transplant Proc 2020;52:3125-8. [PMID: 32553506 DOI: 10.1016/j.transproceed.2020.02.166] [Reference Citation Analysis]
27 Ali A, Gyurova IE, Waggoner SN. Mutually assured destruction: the cold war between viruses and natural killer cells. Curr Opin Virol 2019;34:130-9. [PMID: 30877885 DOI: 10.1016/j.coviro.2019.02.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
28 Bunk S, Ponnuswamy P, Trbic A, Malisauskas M, Anderle H, Weber A, Ilas J, Winkler AM, Butterweck HA, Teschner W, Scheiflinger F, Hermann C, Reipert BM. IVIG induces apoptotic cell death in CD56dim NK cells resulting in inhibition of ADCC effector activity of human PBMC. Clinical Immunology 2019;198:62-70. [DOI: 10.1016/j.clim.2018.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Sung AP, Tang JJ, Guglielmo MJ, Redelman D, Smith-Gagen J, Bateman L, Hudig D. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. J Immunol Methods 2018;452:63-72. [PMID: 29113954 DOI: 10.1016/j.jim.2017.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
30 Goletz C, Lischke T, Harnack U, Schiele P, Danielczyk A, Rühmann J, Goletz S. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Front Immunol 2018;9:1614. [PMID: 30061887 DOI: 10.3389/fimmu.2018.01614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
31 Samarani S, Sagala P, Jantchou P, Grimard G, Faure C, Deslandres C, Amre DK, Ahmad A. Phenotypic and Functional Changes in Peripheral Blood Natural Killer Cells in Crohn Disease Patients. Mediators Inflamm 2020;2020:6401969. [PMID: 32148442 DOI: 10.1155/2020/6401969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol 2019;16:430-41. [PMID: 30778167 DOI: 10.1038/s41423-019-0206-4] [Cited by in Crossref: 112] [Cited by in F6Publishing: 111] [Article Influence: 37.3] [Reference Citation Analysis]
33 Ghaemdoust F, Keshavarz-fathi M, Rezaei N. Natural killer cells and cancer therapy, what we know and where we are going. Immunotherapy 2019;11:1231-51. [DOI: 10.2217/imt-2019-0040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Dahlén E, Veitonmäki N, Norlén P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother 2018;6:3-17. [PMID: 29998217 DOI: 10.1177/2515135518763280] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 23.8] [Reference Citation Analysis]
35 Varani M, Auletta S, Signore A, Galli F. State of the Art of Natural Killer Cell Imaging: A Systematic Review. Cancers (Basel) 2019;11:E967. [PMID: 31324064 DOI: 10.3390/cancers11070967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
36 Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D Ligands in Immuno-Oncology. Front Immunol 2021;12:713158. [PMID: 34394116 DOI: 10.3389/fimmu.2021.713158] [Reference Citation Analysis]
37 Zahavi D, AlDeghaither D, O'Connell A, Weiner LM. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther 2018;1:7-12. [PMID: 33928217 DOI: 10.1093/abt/tby002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
38 Ferris RL, Lenz HJ, Trotta AM, García-Foncillas J, Schulten J, Audhuy F, Merlano M, Milano G. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev 2018;63:48-60. [PMID: 29223828 DOI: 10.1016/j.ctrv.2017.11.008] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 14.6] [Reference Citation Analysis]
39 Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 2018;51:146-53. [PMID: 29605760 DOI: 10.1016/j.coi.2018.03.013] [Cited by in Crossref: 106] [Cited by in F6Publishing: 101] [Article Influence: 26.5] [Reference Citation Analysis]
40 Poggi A, Villa F, Fernadez JLC, Costa D, Zocchi MR, Benelli R. Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. Cancers (Basel) 2021;13:3417. [PMID: 34298630 DOI: 10.3390/cancers13143417] [Reference Citation Analysis]
41 Chen J, Fan Y, Cui B, Li X, Yu Y, Du Y, Chen Q, Feng Y, Zhang P. HMGN2: An Antitumor Effector Molecule of γδT Cells. J Immunother 2018;41:118-24. [PMID: 29401165 DOI: 10.1097/CJI.0000000000000211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Bopp T, Schild H. [Immunological foundations of modern (tumor) immunotherapy]. Pathologe 2018;39:492-7. [PMID: 30327859 DOI: 10.1007/s00292-018-0517-8] [Reference Citation Analysis]
43 Fu X, Tao L, Wu W, Zhang X. Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells. Mol Ther Oncolytics 2020;19:33-46. [PMID: 33024817 DOI: 10.1016/j.omto.2020.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
44 Nightingale J, Lum B, Ladwa R, Simpson F, Panizza B. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochim Biophys Acta Rev Cancer 2021;1875:188523. [PMID: 33600823 DOI: 10.1016/j.bbcan.2021.188523] [Reference Citation Analysis]
45 Rezvani K. Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transplant 2019;54:785-8. [PMID: 31431708 DOI: 10.1038/s41409-019-0601-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
46 Miazek-Zapala N, Slusarczyk A, Kusowska A, Zapala P, Kubacz M, Winiarska M, Bobrowicz M. The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 2021;10:1511. [PMID: 34203935 DOI: 10.3390/cells10061511] [Reference Citation Analysis]
47 [DOI: 10.1101/648501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
48 Di Vito C, Mikulak J, Zaghi E, Pesce S, Marcenaro E, Mavilio D. NK cells to cure cancer. Semin Immunol 2019;41:101272. [PMID: 31085114 DOI: 10.1016/j.smim.2019.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
49 Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol 2021. [PMID: 34117484 DOI: 10.1038/s41577-021-00558-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
50 Li Y, Sun R. Tumor immunotherapy: New aspects of natural killer cells. Chin J Cancer Res 2018;30:173-96. [PMID: 29861604 DOI: 10.21147/j.issn.1000-9604.2018.02.02] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
51 Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol 2021;14:21. [PMID: 33514401 DOI: 10.1186/s13045-020-01024-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
52 Kucuksezer UC, Aktas Cetin E, Esen F, Tahrali I, Akdeniz N, Gelmez MY, Deniz G. The Role of Natural Killer Cells in Autoimmune Diseases. Front Immunol 2021;12:622306. [PMID: 33717125 DOI: 10.3389/fimmu.2021.622306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
53 Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G. Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. BMC Cancer 2019;19:899. [PMID: 31500586 DOI: 10.1186/s12885-019-6109-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
54 Hirukawa A, Singh S, Wang J, Rennhack JP, Swiatnicki M, Sanguin-Gendreau V, Zuo D, Daldoul K, Lavoie C, Park M, Andrechek ER, Westbrook TF, Harris LN, Varadan V, Smith HW, Muller WJ. Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell Rep 2019;29:249-257.e8. [PMID: 31597089 DOI: 10.1016/j.celrep.2019.08.105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
55 Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila M, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, Kahl BS, Kim MY, Cooper ML, DiPersio JF, Berrien-Elliott MM, Fehniger TA. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood 2020;136:2308-18. [PMID: 32614951 DOI: 10.1182/blood.2020006619] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 35.0] [Reference Citation Analysis]
56 Tanaka J. Recent advances in cellular therapy for malignant lymphoma. Cytotherapy 2021;23:662-71. [PMID: 33558145 DOI: 10.1016/j.jcyt.2020.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Strohl WR. Current progress in innovative engineered antibodies. Protein Cell 2018;9:86-120. [PMID: 28822103 DOI: 10.1007/s13238-017-0457-8] [Cited by in Crossref: 151] [Cited by in F6Publishing: 123] [Article Influence: 30.2] [Reference Citation Analysis]
58 Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol Med Chir (Tokyo) 2018;58:405-21. [PMID: 30249919 DOI: 10.2176/nmc.ra.2018-0141] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 22.0] [Reference Citation Analysis]
59 Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P. Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. Oncoimmunology 2018;7:e1393597. [PMID: 29308327 DOI: 10.1080/2162402X.2017.1393597] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
60 Lai ZZ, Ruan LY, Wang Y, Yang HL, Shi JW, Wu JN, Qiu XM, Ha SY, Shen HH, Yang SL, Zheng ZM, Shao J, Ye JF, Li MQ. Changes in subsets of immunocytes in endometrial hyperplasia. Am J Reprod Immunol 2020;84:e13295. [PMID: 32583503 DOI: 10.1111/aji.13295] [Reference Citation Analysis]
61 Patra T, Ray RB, Ray R. Strategies to Circumvent Host Innate Immune Response by Hepatitis C Virus. Cells 2019;8:E274. [PMID: 30909456 DOI: 10.3390/cells8030274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
62 Cotchett KR, Dittel BN, Obeidat AZ. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. Mult Scler Relat Disord 2021;49:102787. [PMID: 33516134 DOI: 10.1016/j.msard.2021.102787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Malmberg KJ, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren HG. Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol 2017;31:20-9. [PMID: 28888619 DOI: 10.1016/j.smim.2017.08.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 24.0] [Reference Citation Analysis]
64 Dubois SP, Miljkovic MD, Fleisher TA, Pittaluga S, Hsu-Albert J, Bryant BR, Petrus MN, Perera LP, Müller JR, Shih JH, Waldmann TA, Conlon KC. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies. J Immunother Cancer 2021;9:e002193. [PMID: 33883258 DOI: 10.1136/jitc-2020-002193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sacchetti B, Botticelli A, Pierelli L, Nuti M, Alimandi M. CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. Int J Mol Sci 2019;20:E1903. [PMID: 30999624 DOI: 10.3390/ijms20081903] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
66 Levin SD, Evans LS, Bort S, Rickel E, Lewis KE, Wu RP, Hoover J, MacNeil S, La D, Wolfson MF, Rixon MW, Dillon SR, Kornacker MG, Swanson R, Peng SL. Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains. Front Immunol 2019;10:3086. [PMID: 32038630 DOI: 10.3389/fimmu.2019.03086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Seminars in Immunology 2017;31:37-54. [DOI: 10.1016/j.smim.2017.07.009] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 25.0] [Reference Citation Analysis]
68 Rawding PA, Bu J, Wang J, Kim DW, Drelich AJ, Kim Y, Hong S. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1752. [PMID: 34414690 DOI: 10.1002/wnan.1752] [Reference Citation Analysis]
69 Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother 2017;66:1367-75. [PMID: 28623459 DOI: 10.1007/s00262-017-2031-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 12.4] [Reference Citation Analysis]
70 Shi L, Liu T, Gross ML, Huang Y. Recognition of Human IgG1 by Fcγ Receptors: Structural Insights from Hydrogen-Deuterium Exchange and Fast Photochemical Oxidation of Proteins Coupled with Mass Spectrometry. Biochemistry 2019;58:1074-80. [PMID: 30666863 DOI: 10.1021/acs.biochem.8b01048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
71 Belizário JE, Neyra JM, Setúbal Destro Rodrigues MF. When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. Innate Immun 2018;24:452-65. [PMID: 30236030 DOI: 10.1177/1753425918800200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
72 Shaffer TM, Aalipour A, Schürch CM, Gambhir SS. PET Imaging of the Natural Killer Cell Activation Receptor NKp30. J Nucl Med 2020;61:1348-54. [PMID: 32532927 DOI: 10.2967/jnumed.119.233163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Waldmann TA, Miljkovic MD, Conlon KC. Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. J Exp Med 2020;217:e20191062. [PMID: 31821442 DOI: 10.1084/jem.20191062] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
74 Karampatzakis A, Brož P, Rey C, Önfelt B, Cruz De Matos GDS, Rycroft D, Ambrose A, Davis DM. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells. Front Immunol 2021;12:641521. [PMID: 33796107 DOI: 10.3389/fimmu.2021.641521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J. The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front Immunol. 2017;8:631. [PMID: 28620386 DOI: 10.3389/fimmu.2017.00631] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 16.4] [Reference Citation Analysis]
76 Stephen ZR, Zhang M. Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer. Adv Healthc Mater 2021;10:e2001415. [PMID: 33236511 DOI: 10.1002/adhm.202001415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
77 Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L. The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Curr Oncol 2021;28:1077-93. [PMID: 33652996 DOI: 10.3390/curroncol28020105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
78 Ferretti E, Carlomagno S, Pesce S, Muccio L, Obino V, Greppi M, Solari A, Setti C, Marcenaro E, Della Chiesa M, Sivori S. Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance. Cancers (Basel) 2020;12:E3705. [PMID: 33321719 DOI: 10.3390/cancers12123705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Poggi A, Benelli R, Venè R, Costa D, Ferrari N, Tosetti F, Zocchi MR. Human Gut-Associated Natural Killer Cells in Health and Disease. Front Immunol 2019;10:961. [PMID: 31130953 DOI: 10.3389/fimmu.2019.00961] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
80 Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131:49-57. [PMID: 29118009 DOI: 10.1182/blood-2017-06-741041] [Cited by in Crossref: 164] [Cited by in F6Publishing: 151] [Article Influence: 32.8] [Reference Citation Analysis]
81 Wang F, Luo Y, Zhang L, Younis M, Yuan L. Down-regulation of LncRNA 2900052N01Rik inhibits LPS-induced B cell function in vitro. Cell Immunol 2021;363:104321. [PMID: 33773377 DOI: 10.1016/j.cellimm.2021.104321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 St-Pierre F, Bhatia S, Chandra S. Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies. Cancers (Basel) 2021;13:1988. [PMID: 33924213 DOI: 10.3390/cancers13081988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
83 Ivanchenko M, Thorlacius GE, Hedlund M, Ottosson V, Meneghel L, Björkander S, Ossoinak A, Tingström J, Bremme K, Sverremark-Ekström E, Gemzell-Danielsson K, Sonesson SE, Chemin K, Wahren-Herlenius M. Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block. Ann Rheum Dis 2021;80:194-202. [PMID: 33004330 DOI: 10.1136/annrheumdis-2019-216786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Zong S, Hoffmann C, Mané-Damas M, Molenaar P, Losen M, Martinez-Martinez P. Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression? Front Immunol 2017;8:752. [PMID: 28725222 DOI: 10.3389/fimmu.2017.00752] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
85 Sailliet N, Brosseau C, Robert J, Brouard S. Role of JAK inhibitors and immune cells in transplantation. Cytokine & Growth Factor Reviews 2019;47:62-73. [DOI: 10.1016/j.cytogfr.2019.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE. Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies? Vaccines (Basel) 2018;6:E79. [PMID: 30477198 DOI: 10.3390/vaccines6040079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]